Skip to main content
. 2019 Mar 5;16:17. doi: 10.1186/s12986-019-0344-9

Fig. 6.

Fig. 6

Confirmation of PPARγ agonists pioglitazone and antagonist GW9662 on PPARγ expression in the livers (a) and gastrocnemius (b) of EDM rats. Exercise-induced increases of PPARγ in the livers (a) and gastrocnemius (b) of EDM rats were reversed by PPARγ antagonist GW9662 and further increased by PPARγ agonist pioglitazone at mRNA (upper) and protein (middle) levels. The blots of PPARγ were quantified by Tanon software and normalized against β-actin or GAPDH, then the normalized numbers were compared (bottom) between different groups. DM: diabetes mellitus; EDM: exercised DM; EDP: EDM + pioglitazone; EDG: EDM + GW9662. *P<0.05, **P<0.01 vs DM. #P<0.05, ##P<0.01 vs EDM